When Cogan's syndrome presents with cochleo-vestibular involvement at moderate to severe intensity, the clinical picture is particularly serious. This scenario carries a poor prognosis for auditory and vestibular function and demands rapid initiation of appropriate therapy.

Clinical scenario: Moderate to severe cochleo-vestibular involvement in Cogan's syndrome. Unlike ocular manifestations of the disease, cochleo-vestibular involvement has a poor prognosis and justifies the rapid introduction of immunosuppressive treatment.

Treatment approach (partial overview)

First-line management combines systemic corticosteroid therapy with an immunosuppressant agent. An adjunctive local intervention targeting the inner ear may also be considered alongside systemic treatment. The complete structured regimen — including agent selection, sequencing, and all clinical parameters — is available in the full protocol.

References

Unlike ocular involvement, cochleo-vestibular involvement has a poor prognosis and justifies the rapid introduction of immunosuppressive treatment or biologic therapy.
Oral steroid therapy remains the most commonly used first-line treatment at a dosage of 1 mg/kg/day (not exceeding 60 mg/day unless in exceptional circumstances), sometimes preceded by intravenous methylprednisolone boluses (15 mg/kg/day for 3 days not exceeding 1 g per bolus).
In moderate to severe forms or in case of failure or inadequate response, immunosuppressants are recommended (methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide) according to their use in vasculitis.
Intratympanic steroid injections may be offered as adjunctive therapy to systemic treatment.

DOI: 10.1016/j.revmed.2024.09.007

View source ↗

Treatment of Cogan's Syndrome with Moderate to Severe Cochleo-Vestibular Involvement

References